-
Mashup Score: 1U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease - Agepha Pharma US - 11 month(s) ago
LODOCO® (colchicine, 0.5 mg tablets) reduces cardiac event risk in adult patients with established Atherosclerotic Cardiovascular Disease (ASCVD) by an additional 31% on top of standard of care including high intensity statins.
Source: Agepha Pharma USCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease - Agepha Pharma US - 11 month(s) ago
LODOCO® (colchicine, 0.5 mg tablets) reduces cardiac event risk in adult patients with established Atherosclerotic Cardiovascular Disease (ASCVD) by an additional 31% on top of standard of care including high intensity statins.
Source: Agepha Pharma USCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 12U.S. FDA Approves First Anti-Inflammatory Drug for Cardiovascular Disease - Agepha Pharma US - 11 month(s) ago
LODOCO® (colchicine, 0.5 mg tablets) reduces cardiac event risk in adult patients with established Atherosclerotic Cardiovascular Disease (ASCVD) by an additional 31% on top of standard of care including high intensity statins.
Source: Agepha Pharma USCategories: Latest Headlines, Partners & KOLsTweet-
RT @drpablocorral: 👉FDA approves CV version of colchicine for patients with residual inflammatory risk https://t.co/JFwM1nircA https://t.c…
-
RT @CardioIAN: @CardioIAN @MihaiTrofenciuc #CardioTwitter https://t.co/0i9LKCyNMP